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Introduction
Surveys on the prevalence of multiple sclerosis (MS)
carried out in large populations in Spain before 1992
used various diagnostic criteria and were based almost
exclusively on hospital records [1, 2, 6, 8, 14, 16, 18, 25,
28, 29]. These studies defined Spain as an area of low to
medium risk for MS, according to Kurtzke [12]. Using
every reasonable information source available for popu-
lations under 100,000, prevalence rates between 32 and
65 per 100,000 in northern and southern Spain have
been obtained [3, 7, 17, 30]. Dean and Middleton used
the same methods and reported similar figures for Sicily
and Cyprus, at a latitude similar to that of Spain, [4, 15,
26].
Except for a previous survey in Salamanca and
Zamora [25], there are no recent data on the frequency of
MS in our region, located 200km north of Madrid. Nev-
ertheless, the number of followed-up patients in our
health area suggested the prevalence of MS here to be
similar to that recently reported for the north and south
of our country.
Study population and methods
The area investigated includes six health zones, each of
with its own health center and with a single outpatient
clinic of specialties run by the Neurology Department of
the Hospital Universitario of Valladolid. These six areas
are within the city of Valladolid and comprise a total area
of 197 km2 (41°39 ¢ N–4°44 ¢ W) and a population of 92,632
(November 1996). The region has a continental climate
with a mean temperature of 12.4°C. Its average altitude is
698 m above sea level (Fig.1). Economic activity is fun-
damentally industrial, largely car and machinery manu-
facturing, and services. The population level in Valladolid
is stable, having increased only slightly over the past 15
years. There is a high racial uniformity and migratory
movements are rare.
The survey was carried out over a 2-year period from
September 1995 to August 1997. The day of 1 March
1997 was chosen as the prevalence day since this was the
date when all the patients began to be checked for the sec-
ond time to confirm they were still alive and living in the
area. Poser’s classification of MS was used, and only
those persons with probable or definite MS were included
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[22]. Disability was assessed using the Expanded Disabil-
ity Status Scale (EDSS) of Kurtzke [10]. A disability of
0–3 was considered mild disability, 4–6 moderate disabil-
ity, and 7–9.5 severe disability. A progression index was
defined as the ratio of the disability status (EDSS) to the
duration of the disease in years [21]. The type of progres-
sion was defined according to the consensus criteria es-
tablished by Lublin et al. [13]. The onset of MS was de-
termined by interviewing patients and reviewing their
medical records, and the classification of definite and
probable signs and symptoms of MS proposed by Poser
was used [19].
Multiple methods for case ascertainment were used.
Records of both Valladolid hospitals (Hospital Universi-
tario and Hospital Universitario del Río-Hortega), data
from the Neurology Service of the Hospital Universitario
and the records from outpatient clinics of specialties were
reviewed, searching for the code number 340 (MS). Fur-
ther information was obtained from 41 general practition-
ers in the area by periodically interviewing medical coor-
dinators from each one of the six health zones. Other
sources of information included private neurologists (4),
internists (14), records of evoked potential studies in Hos-
pital Universitario, a home hospitalization unit, welfare
workers, and the local MS patient association. Informa-
tion from the city’s two units of magnetic resonance imag-
ing (MRI) could not be obtained as their files were not on
a data base. Searching for nonidentified patients, two
symposia for relatives and patients were held and reported
by the public media.
All possible MS patients were examined by two neu-
rologists. A second examination was carried out by the
same physician in all cases. MS had to be confirmed by
both physicians for the diagnosis to be accepted.
Adjusted prevalence rates were calculated by the direct
method [11] using 5-year groupings, with the total Span-
ish population (1991 census) as a standard. Confidence
intervals (95%) were computed assuming the Poisson dis-
tribution [27]. The chi-square test was used to analyze the
homogeneity in the distribution of patients over the six
health zones [9]. The survey was reviewed by the Hospi-
tal Universitario of Valladolid Research Committee and
by the Board of the ONCE Foundation for the cooperation
and social integration of the disabled.
Results
After an intensive search, 54 definite or probable MS pa-
tients were ascertained, all alive and living in the area on
1 March 1997 (18 men and 36 women). Fifty-one patients
had definite MS (18 men and 33 women), including 4
with laboratory-confirmed MS. Three women had clini-
cally probable MS. The crude prevalence rate found in the
area was 58.3 per 100,000 (95% CI: 43.7–75.7). The
prevalence for clinically definite MS alone was 55.1 per
100,000. Age- and sex-specific prevalence rates are
shown in Table 1. The distribution of cases within the
study area, analyzed according to the six health zones,
was uniform (chi-square = 7.2; d.f. = 5; P = 0.2). Crude
prevalences and age- and sex-adjusted prevalence rates of
the 1991 Spanish population in the most recent epidemio-
logical studies carried out in Spain are shown in Table 2.
Forty-five patients were visited or admitted to hospital
during the study. Five patients were identified by hospital
records. One patient was being visited by a private neu-
rologist and another patient by an internist. The collabora-
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Fig.1 Map of Spain, with the
province of Valladolid (left)
and the study area (right). The
areas of Gijón, Osona, Teruel,
and Vélez-Málaga are also
shown
tion of the local MS patient association allowed us to find
one patient not identified by other methods. A general
practitioner reported the case of a woman suffering from
MS for 24 years who had not been visited by a neurologist
for the past 10 years. The remaining methods for case as-
certainment detected no patient not already known by the
local neurologists.
Mean age at onset was 27.3 years (men 28.7, women
26.6) and mean age on the prevalence day was 36.1 years
(men 37.6, women 35.3). The mean period between the
first symptom and the prevalence day was 8.7 years (men
8.8; women 8.6). The mean diagnostic delay was 3 years
(range 0–23). Sensory symptoms were the most common
at onset (55%), followed by pyramidal tract symptoms
(49%), brainstem symptoms (31%), cerebellar symptoms
(24%), and optic neuritis (14%).
Cranial MRI was performed in all patients except
three, with abnormal results in 98%. In addition, the re-
sults of 32% of spinal MRI studies were also abnormal.
The median and interquartile EDSS range in clinically
definite patients was 3.0 [1.5–5.0; men 3.5 (1.5–5.6),
women 2.5 (1.0–4.3)]. The mean EDSS score was 3.4.
The mean progression index was 0.4. Among these pa-
tients 58% were only slightly or not disabled (EDSS ≤
3.0), and 13% were severely disabled (EDSS ‡ 7.0). Nine
patients were alive after 15 years of the disease; one had
low disability, four moderate, and four severe.
The clinical course was relapsing-remitting in 37 pa-
tients (68%; 11 men, 26 women), primary-progressive in
11 (20%; 4 men, 7 women), and 6 patients with an initial
relapsing-remitting evolution had developed a secondary
progressive clinical course (3 men, 3 women).
Thirty-four patients were born in Valladolid (63%), ten
in adjacent provinces (18%), and the rest in other places
in Spain, except two patients born in France and Switzer-
land, respectively. A family history of MS were found in
two women.
Nine patients were excluded from the survey because
they had been misdiagnosed. Two of these had a cervical
spondylotic myelopathy; one had an Arnold-Chiari mal-
formation; three had hyperintense lesions on cranial MRI
that according to their vascular risk factors, clinical
course, and age was of ischemic origin; one was diag-
nosed as having Childer disease, though not confirmed by
necropsy; one showed typical hyperintense lesions on cra-
nial MRI although his symptoms were considered sec-
ondary to a large cervical disk herniation; and one suf-
fered from hysteria.
Discussion
The results of our study, together with those obtained in
other Spanish regions using a similar methodology [3, 7,
17, 30], confirm our country as a high risk area for MS,
with prevalence rates between 50 and 60 per 100,000. We
believe that only a single further study in southern Spain
is needed to confirm the survey findings of Fernández et
al. [6, 7] in Málaga.
Comparison of adjusted prevalence rates to Spanish
populations, except for the results of Modrego-Pardo et al.
in Teruel [17], show few differences among the recent
surveys carried out in Spain. The size of the study area,
with a total population of 143,000 inhabitants, health-care
dispersion, duration of the survey, and a high emigration
rate can explain the prevalence rate in Teruel.
A number of features lend additional credence to the
figures from our study. The study population has a high
demographic stability and racial uniformity. The area has
a good sanitary infrastructure, with well-developed health
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Table 1 Age- and sex-specific
prevalence rates (MS multiple
sclerosis, M men, W women)
Age Population MS patients Prevalence/100,000
(years)
M W Total M W Total M W Total
≤ 19 9,044 8,822 17,866 2 2 4 22.1 22.7 22.4
20–29 9,412 9,579 18,991 6 12 18 63.7 125.3 94.8
30–39 6,067 6,580 12,647 2 12 14 33 182.4 110.7
40–49 6,014 6,844 12,858 3 5 8 49.9 73.1 62.2
50–59 5,794 5,899 11,693 5 4 9 86.3 67.8 77
‡ 60 7,921 10,656 18,577 – 1 1 – 9.4 5.4
All 44,252 48,380 92,632 18 36 54 40.7 74.4 58.3
Table 2 Comparison of the most recent prevalence studies in
Spain (MS multiple sclerosis, CI confidence interval)
Popu- MS pa- Crude Age- and
lation tients prevalence sex-adjusted
[CI 95%]a prevalenceb
Vélez-Málaga [7] 36,014 19 52 [31.7–82.2] 61
Osona [3] 71,985 42 58 [42.0–78.7] 60
Gijón [30] 33,775 22 65 [40.8–98.3] 59
Teruel [17] 143,680 46 32 [22.8–41.3] 35
Valladolid 92,632 54 58 [43.7–75.7] 53
a Crude prevalence per 100,000 population
b Age- and sex-adjusted prevalence per 100,000 in the 1991 Span-
ish population
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services, and neurological care is focused in a single neu-
rology department. Computerization of both hospital
records and neurology service data made case ascertain-
ment easier. Multiple sources of information as by Fer-
nández et al. were used [5], allowing us to identify nine
patients (16%) who were not being visited by local neu-
rologists. If we had not used all these information sources,
the prevalence figures would have been 48.6 instead of
58.3 per 100,000. Finally, the patient distribution in the
studied area was homogeneous, showing easy and uni-
form access to neurological services.
It has been proposed as a measurement of the reliabil-
ity of MS prevalence studies that the ratio of patients hav-
ing a low degree of disability (EDSS ≤ 3.0) must be close
to 70% [24]. This estimation has been carried out accord-
ing to the concept of onset-adjusted prevalence rate pro-
posed by Poser, after his experience on a survey in Iceland
[23]. This measures the number of symptomatic MS pa-
tients (diagnosed or not) in an ethnically homogeneous
population who live to the age of puberty in the same nat-
urally defined geographical area [20]. This measurement
requires case ascertainment to be extended at least 2 years
after the prevalence date to increase the probability of di-
agnosing all the patients in the area. In our study, using
the traditional concept of prevalence, the ratio of patients
with low disability was 58%. This lower percentage sug-
gests that there may be patients who have not consulted
health services for their symptoms yet.
The mean age on the prevalence day (36.1 years), the
mean duration of the disease (8.7 years), the reduced per-
centage of patients with a secondary progressive course,
and the low number of patients older than 60 years sug-
gest that there are some patients in the area who were not
identified in this study. Our accumulated experience could
clarify this point in a future survey.
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